Experts report toxicity reduction in polymeric prodrug pre-clinical trials
Preclinical studies have shown that a newly developed polymeric prodrug when administered subcutaneously (SC), reduces the production of hemotoxic metabolites in the liver and the risk of hemolytic anemia, thereby potentially modifying